Miranda Adrian reported grant involving 133,341 derivative units of Neuraxis, INC at $6.28 for $837k on Aug 13, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CMO, SVP Science & Tech
CMO, SVP Science & Tech
Filed Aug 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$837,381.48Shares × reported price
Shares traded
133,341RSU
Price per share
$6.28Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
133,341Direct
Trade date
Aug 13, 2026Grant
Filed
Aug 17, 2026, 6:36 PM ET4-day reporting delay
Accession
0001493152-26-038829Code A · Transaction 1290
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

NRXS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NRXS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago +10%1d ago −0.2%
Returns since7d −3.3%30d +11%90d180d1y

Footnotes in full

F1: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.